To study the role of hyaluronic acid (HA) in polidocanol (POL) foam.
Methods
The dose-dependent effect of HA-POL on cultured human umbilical vein endothelial cells (HUVECs) as well as foam stability was evaluated by measuring optical density (OD) values and foam half-life time (FHT), respectively. An in vitro model was utilized for estimating the foam blood-displacement capacity by adopting maximum displacement distance (MDD) and displacement time. A comparison of foam viscosity was also carried out.
Results
The OD values of HUVECs treated with HA first increased and then decreased with the growing dosage of HA while cells treated with HA-POL died. Both FHT and displacement time were prolonged statistically with a gradually enhanced foam viscosity. As to MDD, there were no significant differences.
Conclusions
HA was found to promote HUVECs proliferation slightly, but this was almost negligible when compared to the cell-killing capacity of 1% POL. The viscosity of POL foam was enhanced by HA indicating its positive correlation with both stability and displacement capacity of POL foam.
Guidelines of care for sclerotherapy treatment of varicose and telangiectatic leg veins. American Academy of Dermatology. J Am Acad Dermatol. 1996;34:523–528.
ChenAWLiuYRLiK, et al.An Investigation on the Influence of Hyaluronic Acid on Polidocanol Foam Stability. Dermatol Surg2016; 42: 56–58.
4.
ChenAWLiuSHHuangYY, et al.Preliminary experience with more stable polidocanol foam in sclerotherapy of head and neck venous malformations. Dermatol Surg2018; 44: 1421–1426.
5.
TessariLCavezziAFrulliniA. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg2001; 27: 58–60.
6.
CarugoDAnkrettDNO’ByrneV, et al.A novel biomimetic analysis system for quantitative characterisation of sclerosing foams used for the treatment of varicose veins. J Mater Sci2013; 24: 1417–1423.
7.
SegurJBOberstarHE. Viscosity of glycerol and its aqueous solutions. Ind Eng Chem2002; 43: 2117–2120.
8.
PriesARNeuhausDGaehtgensP. Blood viscosity in tube flow: dependence on diameter and hematocrit. Am J Physiol1992; 6: 263.
9.
RayahinJEBuhrmanJSZhangY, et al.High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng2015; 1: 481–493.
10.
ChangWHLiuPYLinMH, et al.Applications of Hyaluronic Acid in Ophthalmology and Contact Lenses. Molecules2021; 26: 2485.
11.
LeeYSugiharaKGillillandMG, et al.Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater2020; 19: 118–126.
12.
WeberGCBuhrenBASchrumpfH, et al.Clinical Applications of Hyaluronidase. Adv Exp Med Biol2019; 1148: 255–277.
13.
MurakamiTOtsukiSOkamotoY, et al.Hyaluronic acid promotes proliferation and migration of human meniscus cells via a CD44-dependent mechanism. Connect Tissue Res2019; 60: 117–127.
14.
HallCLYangBYangX, et al.Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell1995; 82: 19–28.
15.
ParkDKimYKimH, et al.Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFβ receptor interaction via CD44-PKCδ. Mol Cells2012; 33: 563–574.
16.
MolWFurukawaHSasakiS, et al.Evaluation of the sclerotherapeutic efficacy of ethanol, polidocanol, and OK-432 using an in vitro model. Dermatol Surg2007; 33: 1452–1459.
17.
PetersonJDGoldmanMP. An investigation into the influence of various gases and concentrations of sclerosants on foam stability. Dermatol Surg2011; 37: 12–17.
18.
CameronEChenTConnorD, et al.Sclerosant foam structure and stability is strongly influenced by liquid air fraction. Eur J Vasc Endovasc Surg2013; 46: 488–494.
19.
NastasaVSamarasKAmpatzidisCH, et al.Properties of polidocanol foam in view of its use in sclerotherapy. Int J Pharm2015; 478: 588–596.
20.
BaiTLiuYLiuJ, et al.A comparison of different surfactants on foam stability in foam sclerotherapy in vitro. J Vasc Surg2019; 69: 581–591.
21.
DoderoAWilliamsRGagliardiS, et al.A micro-rheological and rheological study of biopolymers solutions: Hyaluronic acid. Carbohydr Polym2019; 203: 349–355.
22.
BradyAP RS. The measurement of foam stability. J Am Chem Soc1944; 66: 1348–1356.
23.
Del Castillo-SantaellaTYangYMartínez-GonzálezI, et al.Effect of Hyaluronic Acid and Pluronic-F68 on the Surface Properties of Foam as a Delivery System for Polidocanol in Sclerotherapy. Pharmaceutics2020; 12: 1–16.
24.
WeissMAHsuJTSNeuhausI, et al.Consensus for sclerotherapy. Dermatol Surg2014; 40: 1309–1318.
25.
CavezziAFrulliniARicciS, et al. Treatment of varicose veins by foam sclerotherapy: Two clinical series. Phlebology2002; 17: 13–18.
26.
CarugoDAnkrettDNO’ByrneV, et al.The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model. J Mater Sci2015; 26: 258.
27.
CavezziATessariL. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology2009; 24: 247–251.
28.
PetersonJDGoldmanMP. An investigation on the influence of glycerin on sclerosant foam stability. Phlebology2011; 26: 232–234.
29.
MartinAHGrolleKBosMA, et al.Network forming properties of various proteins adsorbed at the air/water interface in relation to foam stability. J Colloid Interf Sci2002; 254: 175–183.
30.
MeghdadiAJonesSAPatelVA, et al.Foam-in-vein: A review of rheological properties and characterization methods for optimization of sclerosing foams. J Biomed Mater Res B Appl Biomater2021; 109: 69–91.
31.
WonYYRamkrishnaD. Revised Formulation of Fick’s, Fourier’s, and Newton’s Laws for Spatially Varying Linear Transport Coefficients. ACS omega2019; 4: 11215–11222.
32.
GuptaRCLallRSrivastavaA, et al. Hyaluronic Acid: Molecular Mechanisms and Therapeutic Trajectory. Front Vet Sci2019; 6: 192.
33.
SnetkovPZakharovaKMorozkinaS, et al.Hyaluronic Acid: The Influence of Molecular Weight on Structural, Physical, Physico-Chemical, and Degradable Properties of Biopolymer. Polymers (Basel)2020; 12: 1800.
34.
DeLorenziC. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J2014; 34: 584–600.
35.
LaiSWGoldmanMP. Does the relative silicone content of different syringes affect the stability of foam in sclerotherapy?J Drugs Dermatology2008; 7: 399–400.
36.
WollmannJCGoldmanM. The history of sclerosing foams. Dermatol Surg2004; 30: 694–703.
37.
De Aguiar ETDos SantosJBCarvalhoDD. Venous thromboembolism after ultrasound guided foam sclerotherapy. Phlebology2021; 36: 233–239.Dos Santos
38.
BeckittTElstoneAAshleyS. Air versus physiological gas for ultrasound guided foam sclerotherapy treatment of varicose veins. Eur J Vasc Endovasc Surg2011; 42: 115–119.
